Loading…
Elanco Animal Health received a warning for false or misleading promotional claims about Zenrelia (ilunocitinib tablets), a recently approved veterinary drug for canine atopic dermatitis. The company's veterinarian and consumer websites, product brochure, and marketing materials misrepresented the safety and effectiveness of the JAK inhibitor, particularly failing to adequately communicate critical safety information regarding risks of fatal vaccine-induced disease and increased susceptibility to infections that are detailed in the FDA-approved prescribing information. The violations were deemed especially concerning because misleading promotional communications about a newly approved drug class could create dangerous misimpressions regarding patient safety among veterinarians and pet owners.